ERBB2 and gastric cancer: For patients with HER-2+ GC, the results of the KEYNOTE-811 study showed that the objective remission rate (ORR) after first-line treatment with pembrolizumab combined with trastuzumab + chemotherapy was as high as 74.4% [4].